At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Guru Sonpavde, MD, of AdventHealth Cancer Institute, provides an overview of a phase I/II trial in progress on V940 (mRNA-4157) plus pembrolizumab with or without enfortumab vedotin for resected high-risk muscle-invasive urothelial carcinoma.
INTerpath-005: V940 Plus Pembro With or Without EV for Resected High-Risk MIUC
By Guru P. Sonpavde, MD - Last Updated: February 24, 2025Related Posts
Previous research has shown that BLC can provide improved detection rates, mainly for high-risk disease and invasive tumors.
Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.
The panel elaborates on what excites them most about the future of UC research, highlighting promising advancements.
The panel considers the evolving role of ctDNA in guiding adjuvant therapy decisions, highlighting IMvigor011 and MODERN.
The panel shares the NIAGARA findings and results from RETAIN-2 on dose-dense MVAC for bladder preservation.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.